Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe

ENCePP Seal

This study has been awarded the ENCePP seal

Conflicts of interest of investigators

DoIForm_v1.6_Upa AD RMM_JR.pdf

Composition of steering group and observers

Composition of Steering Group and Observers.pdf

Signed code of conduct

Annex3_Declaration-Upa AD RMM_signed.pdf

Signed code of conduct checklist

Annex2_Checklist_Upa AD RMM_signed.pdf

Signed checklist for study protocols

Signed ENCePP checklist for Upa AD RMM v1.0 Study Protocol.pdf

Data sources

• Data source(s):
  National Cancer Register / Cancerregistret

  National Prescribed Drugs Register / Läkemedelsregistret

  Danish registries (access/analysis)
• Data source(s), other:
  The Swedish National Patient register ; The Swedish Cause of Death Register; Swedish Medical Birth Register; SMINET;
• Data sources (types):
  Administrative data (e.g. claims)

  Disease registry

  Drug dispensing/prescription data

  Laboratory data

  Population registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No